Research programme: cancer therapeutics - Metamark Genetics/Janssen
Latest Information Update: 11 Sep 2015
At a glance
- Originator Janssen Biotech; Metamark Genetics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 Sep 2015 No development reported for Cancer in USA (unspecified route)
- 19 Dec 2011 Early research in Cancer in USA (unspecified route)